483 Roundup: FDA Cites Italian, Indian and Chinese Firms
The FDA flagged facilities in Italy, India and China for noncompliances including inadequate testing, complaint handling, and quality data, among other violations.
Source: Drug GMP Report
The FDA flagged facilities in Italy, India and China for noncompliances including inadequate testing, complaint handling, and quality data, among other violations.
Source: Drug GMP Report